Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

NCT00098748 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Optimized Background Therapy (OBT)
DRUG: maraviroc (UK-427,857)
DRUG: Optimized Background Therapy (OBT)
DRUG: maraviroc (UK-427,857)
DRUG: Optimized Background Therapy (OBT)

Sponsor

ViiV Healthcare

Collaborators

[object Object]